Dunlap Ryan 4
4 · CytoDyn Inc. · Filed Mar 24, 2026
Research Summary
AI-generated summary of this filing
CytoDyn (CYDY) Director Ryan Dunlap Receives Award of 574,385 Options
What Happened
Ryan Dunlap, a director of CytoDyn Inc. (CYDY), received a grant of derivative securities covering 574,385 shares on March 20, 2026. The filing reports an acquisition price of $0.00 (i.e., no cash paid at grant) and classifies the award as a derivative (stock option) award. The grant was approved by the Compensation Committee as the annual 2026 award under the company’s 2012 Equity Incentive Plan.
Key Details
- Transaction date: 2026-03-20; Form 4 filed: 2026-03-24 (filed one business day late).
- Reported amount: 574,385 shares; reported acquisition price: $0.00 (derivative award).
- Vesting: The award vests in ~12 equal monthly installments on the same day each month from April 2026 through March 2027 (per footnote).
- Plan: Award issued under the Issuer’s 2012 Equity Incentive Plan, using shares reserved for employees, directors and certain consultants.
- Shares owned after transaction: not specified in the available filing.
- Filing timeliness: filing appears late by one business day (March 24 filing for a March 20 transaction).
Context
This is a compensation grant (option award) rather than an open‑market purchase or sale. Such grants are routine director compensation and do not itself signal a buy or sell decision—options only convert into economic ownership if they vest and are exercised. Retail investors commonly treat purchases as a stronger immediate signal of insider conviction than routine awards.
Insider Transaction Report
- Award
Non-qualified stock option (right to buy)
[F1][F2]2026-03-20+574,385→ 574,385 totalExercise: $0.28Exp: 2036-03-20→ Common Stock (574,385 underlying)
Footnotes (2)
- [F1]This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").
- [F2]The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.